Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 12/20 | 0.69 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.52 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395800 | 1.00 | PNMT (0.69) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL552771 | 0.98 | PNMT (0.67) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| Bromide SCHEMBL7011911 | 0.98 | PNMT (0.67) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL505055 | 0.82 | ASIC3 (1.00) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL29543449 | 0.82 | ASIC3 (0.50) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL552932 | 0.82 | PNMT (1.00) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| SCHEMBL29473102 | 0.82 | PNMT (1.00) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL1017313 | 0.81 | ASIC3 (0.96) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL1266299 | 0.81 | PNMT (0.96) | PNMTASIC3ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL29528420 | 0.81 | PNMT (0.96) | PNMTASIC3ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160375042-A1 | USE OF CAMPTOTHECIN DERIVATIVE IN PREPARING PHARMACEUTICAL USED FOR TREATING MULTIPLE MYELOMA | ZHOU WENQIANG (CN) | 2016-12-29 | — | — | US | claimed |
| EP-3100734-A1 | USE OF CAMPTOTHECIN DERIVATIVE IN PREPARING PHARMACEUTICAL USED FOR TREATING MULTIPLE MYELOMA | Zhou, Wenqiang (CN) | 2016-12-07 | — | — | EP | claimed |
| EP-2727927-B1 | CAMPTOTHECIN DERIVATIVE, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF | ZHOU WENQIANG (CN) | 2016-07-20 | — | — | EP | claimed |
| US-9266911-B2 | Camptothecin derivative, and preparation method thereof, and pharmaceutical composition and application | HUNAN FANGSHENGHUAMEI MEDICAL TECH. CO. LTD. (CN) | 2016-02-23 | — | — | US | claimed |
| EP-2727927-A1 | CAMPTOTHECIN DERIVATIVE, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Zhou, Wenqiang (CN) | 2014-05-07 | — | — | EP | claimed |
| US-20140107342-A1 | CAMPTOTHECIN DERIVATIVE, AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION | HUNAN FANGSHENGHUAMEI MEDICAL TECH. CO. LTD. (CN) | 2014-04-17 | — | — | US | claimed |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-02-09 | — | — | US | claimed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | claimed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| CN-122059934-A | PD-L1 protein degradation targeting chimeric and preparation method and application thereof | 首都医科大学 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026099404-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | QUBIT PHARMACEUTICALS (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741375-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-05-13 | — | — | EP | disclosed |
| CN-122010906-A | Aromatic heterocyclic derivative with S1P receptor modulating activity, and preparation method and application thereof | 沈阳药科大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010905-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2004060882-A1 | CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | WO | disclosed |
| EP-1276739-A2 | HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME | Bristol-Myers Squibb Company (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
| WO-2001081340-A2 | HETEROCYCLES THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| US-5026856-A | Bactericides | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1991-06-25 | — | — | US | disclosed |
| EP-0343560-A2 | Isoindoline derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | PNMT 1909/4885ASIC3 4005/4885ADRA2A 2660/4885 |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | PNMT 3442/4885ASIC3 3650/4885ADRA2A 323/4885 |
| US-20160375042-A1 | USE OF CAMPTOTHECIN DERIVATIVE IN PREPARING PHARMACEUTICAL USED FOR TREATING MULTIPLE MYELOMA | SLC11A2, MCL1, ABCC1 | PNMT 3476/4885ASIC3 4621/4885ADRA2A 3753/4885 |
| US-20140107342-A1 | CAMPTOTHECIN DERIVATIVE, AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION | CA2, F12, CCND2 | PNMT 4580/4885ASIC3 485/4885ADRA2A 3533/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | PNMT 3442/4885ASIC3 3650/4885ADRA2A 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.